Ingevity Corporation (NGVT), a specialty chemicals and carbon materials maker on the NYSE, has been a focal point for investors as management reshapes the portfolio and Wall Street debates whether the recent run has gone far enough. The central question is whether the shares can reach a $80 stock price target — a figure derived from the current set of attributable analyst price targets.
Ingevity has relatively thin sell-side coverage, and estimates have shifted repeatedly as the company restructures. Reviewing current, individually attributable targets yields three figures: BMO Capital (analyst John McNulty) with a Buy rating and a $85 target (October 2026), Jefferies with a Buy rating and a $82 target (February 2026), and Wells Fargo with an Equal Weight rating and a $75 target (June 2026). The arithmetic mean is approximately $80.67, which rounds to a clean $80 central target, with a low-to-high range of $75 to $85.
Views are genuinely split rather than uniformly bullish. The Buy-rated firms emphasize the earnings and free-cash-flow potential of the streamlined business, while the more cautious Equal Weight stance reflects uncertainty as management explores divesting additional units. Notably, several data providers report aggregate figures anywhere from roughly $80 to about $90, a reminder that the "analyst consensus" for this name is fluid and depends heavily on which reports are included and when they were issued.
With the stock near $70.31 and a 52-week range of roughly $45.85 to $79.29, the move to $80 represents about 13.8% upside — a substantial move that would require the shares to clear their prior 52-week high. The path would likely depend on execution of the ongoing portfolio repositioning, in which management has sold the majority of its Industrial Specialties business and is exploring alternatives for its Advanced Polymer Technologies (APT) and road-markings units, while concentrating on activated-carbon performance materials and paving technologies.
Fundamentals have improved: recent quarters showed a return to profitability after a prior-year loss, completion of a multi-year share repurchase program, and fiscal 2026 guidance of roughly $4.80 to $5.20 in earnings per share (EPS). However, the stock trades on an elevated P/E (price-to-earnings) multiple relative to the broader chemicals sector, meaning the path to $80 depends as much on sustaining valuation as on delivering earnings growth.
The chart context is notable. The $80 target sits just above the stock's 52-week high of roughly $79.29, meaning any move toward it would likely test and attempt to break that prior peak. Below the current price, support has built in the $65-to-$70 zone, which held during recent pullbacks after the shares more than doubled off their 52-week low near $45.85. Because $80 is also a round psychological level directly above a proven resistance zone, it functions as a meaningful technical milestone rather than an arbitrary figure.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual analysts do not always state a precise timeframe. Investors watching the $80 objective should monitor the upcoming quarterly earnings report, guidance updates on the divestiture program, and any analyst target revisions. Developments in activated-carbon and battery-materials demand, changes in tariff policy affecting industrial end markets, and the company's progress reducing debt with divestiture proceeds are all relevant to whether the shares can sustain momentum toward the target.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual review alone. For those tracking Ingevity's path toward the $80 level, these signals offer a systematic complement to fundamental research.
The $80 central target is the average of three current analyst price targets — a modest, $75-to-$85 range reflecting real disagreement about Ingevity's restructuring. Reaching it from near $70.31 requires roughly 14% upside, a substantial move that would push the shares above their 52-week high. The bullish case rests on a focused portfolio, recovering profitability, and buybacks, while a rich valuation, soft industrial demand, and execution risk on the remaining divestitures are the principal obstacles. Whether the target is achieved will likely depend on sustained earnings delivery and whether the market continues to reward the streamlined business model. The target is a benchmark for analysis, not a guarantee.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, NGVT has been loosely correlated with FUL. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if NGVT jumps, then FUL could also see price increases.
| Ticker / NAME | Correlation To NGVT | 1D Price Change % | ||
|---|---|---|---|---|
| NGVT | 100% | -0.29% | ||
| FUL - NGVT | 59% Loosely correlated | -2.52% | ||
| AVNT - NGVT | 58% Loosely correlated | +1.11% | ||
| MTX - NGVT | 56% Loosely correlated | -1.83% | ||
| KWR - NGVT | 55% Loosely correlated | -0.42% | ||
| PPG - NGVT | 55% Loosely correlated | -2.19% | ||
More | ||||